2022
NCCN Guidelines® Insights: Hematopoietic Growth Factors, Version 1.2022.
Griffiths EA, Roy V, Alwan L, Bachiashvili K, Baird J, Cool R, Dinner S, Geyer M, Glaspy J, Gojo I, Hicks A, Kallam A, Kidwai WZ, Kloth DD, Kraut EH, Landsburg D, Lyman GH, Mahajan A, Miller R, Nachar V, Patel S, Patel S, Perez LE, Poust A, Riaz F, Rosovsky R, Rugo HS, Simon S, Vasu S, Wadleigh M, Westbrook K, Westervelt P, Berardi RA, Pluchino L. NCCN Guidelines® Insights: Hematopoietic Growth Factors, Version 1.2022. Journal Of The National Comprehensive Cancer Network 2022, 20: 436-442. PMID: 35545171, DOI: 10.6004/jnccn.2022.0026.Peer-Reviewed Original ResearchConceptsChemotherapy-induced anemiaChemotherapy-induced thrombocytopeniaHematopoietic growth factorsFebrile neutropeniaNCCN guidelinesGrowth factorTreatment of FNNCCN Guidelines InsightsIndividual patient's conditionAdult patientsSupportive careNonmyeloid malignanciesClinical managementPatient's conditionPatientsCancer treatmentAppropriate useRecent updatesPreventionGuidelinesTreatmentManagement optionsNeutropeniaThrombocytopeniaSequelae
2020
Considerations for Use of Hematopoietic Growth Factors in Patients With Cancer Related to the COVID-19 Pandemic.
Griffiths EA, Alwan LM, Bachiashvili K, Brown A, Cool R, Curtin P, Geyer MB, Gojo I, Kallam A, Kidwai WZ, Kloth DD, Kraut EH, Lyman GH, Mukherjee S, Perez LE, Rosovsky RP, Roy V, Rugo HS, Vasu S, Wadleigh M, Westervelt P, Becker PS. Considerations for Use of Hematopoietic Growth Factors in Patients With Cancer Related to the COVID-19 Pandemic. Journal Of The National Comprehensive Cancer Network 2020, 19: 1-4. PMID: 32871558, PMCID: PMC9730290, DOI: 10.6004/jnccn.2020.7610.Peer-Reviewed Original ResearchErythrocyte-stimulating agentsHematopoietic growth factorsGrowth factorSARS-CoV-2 infectionPandemic SARS-CoV-2 infectionGranulocyte colony-stimulating factorColony-stimulating factorTreatment of cancerThrombopoietin mimeticsHigh riskSuch growth factorsStimulating agentsPatientsCancerCOVID-19 eraCOVID-19 pandemicInfectionHigh-risk environmentsNeutropeniaThrombocytopeniaMorbidityChemotherapyFactorsAnemiaGroupNCCN Guidelines Insights: Hematopoietic Growth Factors, Version 1.2020.
Becker PS, Griffiths EA, Alwan LM, Bachiashvili K, Brown A, Cool R, Curtin P, Dinner S, Gojo I, Hicks A, Kallam A, Kidwai WZ, Kloth DD, Kraut EH, Landsburg D, Lyman GH, Miller R, Mukherjee S, Patel S, Perez LE, Poust A, Rampal R, Rosovsky R, Roy V, Rugo HS, Shayani S, Vasu S, Wadleigh M, Westbrook K, Westervelt P, Burns J, Keller J, Pluchino LA. NCCN Guidelines Insights: Hematopoietic Growth Factors, Version 1.2020. Journal Of The National Comprehensive Cancer Network 2020, 18: 12-22. PMID: 31910384, DOI: 10.6004/jnccn.2020.0002.Peer-Reviewed Original ResearchMeSH KeywordsAntineoplastic Combined Chemotherapy ProtocolsBiosimilar PharmaceuticalsChemotherapy-Induced Febrile NeutropeniaDrug ApprovalDrug CostsEducation, Medical, ContinuingHematopoietic Cell Growth FactorsHumansMedical OncologyNeoplasmsOncologistsOrganizations, NonprofitPractice Guidelines as TopicRisk FactorsUnited StatesUnited States Food and Drug AdministrationConceptsFebrile neutropeniaNCCN guidelinesHematopoietic growth factorsGrowth factorManagement of FNTreatment of FNSelect patientsSupportive careNonmyeloid malignanciesCancer treatmentAppropriate evaluationAppropriate usePatientsRisk determinationTreatmentImportant updatesGuidelinesNeutropeniaProphylaxisMalignancyCliniciansFactorsCarePrevention
2018
Standardizing goals of care (GoC) documentation for new patients with metastatic disease.
Kidwai W, Engelking C, Pyle J, Chiang A. Standardizing goals of care (GoC) documentation for new patients with metastatic disease. Journal Of Clinical Oncology 2018, 36: 26-26. DOI: 10.1200/jco.2018.36.34_suppl.26.Peer-Reviewed Original ResearchGOC discussionsGOC documentationPatient-centered cancer carePalliative care teamEligible patientsSmart phrasesMetastatic diseaseNursing assessmentPatient assessmentCancer careQuality improvement toolsCare teamMetastatic cancerThird visitNew patientsProvider timeCare documentationPatientsBusy practiceProvider capacityBaseline dataElectronic documentationProvidersImprovement toolsFacilitative strategiesNCCN Guidelines Insights: Neuroendocrine and Adrenal Tumors, Version 2.2018.
Shah MH, Goldner WS, Halfdanarson TR, Bergsland E, Berlin JD, Halperin D, Chan J, Kulke MH, Benson AB, Blaszkowsky LS, Eads J, Engstrom PF, Fanta P, Giordano T, He J, Heslin MJ, Kalemkerian GP, Kandeel F, Khan SA, Kidwai WZ, Kunz PL, Kuvshinoff BW, Lieu C, Pillarisetty VG, Saltz L, Sosa JA, Strosberg JR, Sussman CA, Trikalinos NA, Uboha NA, Whisenant J, Wong T, Yao JC, Burns JL, Ogba N, Zuccarino-Catania G. NCCN Guidelines Insights: Neuroendocrine and Adrenal Tumors, Version 2.2018. Journal Of The National Comprehensive Cancer Network 2018, 16: 693-702. PMID: 29891520, DOI: 10.6004/jnccn.2018.0056.Peer-Reviewed Original ResearchConceptsPrimary neuroendocrine tumorNeuroendocrine tumorsAdrenal tumorsManagement of NETsLocoregional advanced diseaseNCCN Guidelines InsightsAdrenal gland tumorsAdvanced diseaseNCCN guidelinesAdult patientsDistant metastasisGastrointestinal tractGland tumorsTumorsNeuroendocrineManagement optionsGuidelinesPatientsPheochromocytomaMetastasisParagangliomaDiseaseTract